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BURTON ET AL. 2273eters. Twenty-five patients were enrolled (15 randomized to
2.0mg/kg/week and 10 to 4.0mg/kg/week). No new or unexpect-
ed safety signals were observed. After 24 weeks, there were no
improvements versus baseline in the 6MWT, yet numerical
improvements were seen in the 3MSCT with 4.0mg/kg/week.
uKS and pharmacokinetic data suggested no linear relationship
over the 2.0–4.0mg/kg dose range. Overall, an abnormal exercise
capacity (evaluated in 10 and 5 patients in the 2.0 and 4.0mg/kg/
week groups, respectively), impaired muscle strength, and con-
siderable pain were observed at baseline, and there were trends
towards improvements in all domains after treatment. In con-
clusion, preliminary data of this small study in a Morquio A
population with relatively good endurance confirmed the ac-
ceptable safety profile of elosulfase alfa and showed a trend of
increased exercise capacity and muscle strength and decreased
pain.  2015 The Authors. American Journal of Medical Genetics Part A
Published by Wiley Periodicals, Inc.
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INTRODUCTION
Morquio A syndrome, also known as mucopolysaccharidosis
(MPS) IVA, is a lysosomal storage disorder occurring in 1 per
640,000 to 1 per 76,000 live births, depending on the country of
origin [Tomatsu et al., 2011]. Due to a deficiency in the glycos-
aminoglycan (GAG)-degrading enzyme N-acetylgalactosamine-6-
sulfatase (GALNS), undegraded and partially degraded keratan
sulfate (KS) and chondroitin-6-sulfate accumulate in multiple
tissues and organs of Morquio A patients [Yasuda et al., 2013].
This accumulation causes cellular and organ dysfunction leading to
the progressive development of an array of clinical manifestations.
Most apparent are the musculoskeletal and joint issues, including
short-trunk dwarfism and chest, spine, hip, knee, and ankle
abnormalities, atlantoaxial instability, and wrist hypermobility
[Harmatz et al., 2013; Hendriksz et al., 2015a]. Common non-
skeletal manifestations include cardiorespiratory compromise,
spinal cord compression, corneal clouding, hearing loss, hepato-
splenomegaly, and dental abnormalities [Harmatz et al., 2013;
Hendriksz et al., 2013; Hendriksz et al., 2015a]. Most patients
with Morquio A syndrome show reduced endurance and/or mo-
bility [Harmatz et al., 2013], which can be due to musculoskeletal
abnormalities, joint pain, cardiorespiratory compromise, and/or
neurological disease secondary to spinal cord compression.
The only approved disease-modifying therapy currently available
forMorquioA syndrome is enzymereplacement therapy (ERT)with
elosulfasealfa (VIMIZIM
1
, BioMarinPharmaceutical Inc.,Novato).
Several studies provided consistent evidenceof clinicallymeaningful
and sustained improvement in health and function of Morquio A
patients treated with elosulfase alfa at 2.0mg/kg/week as assessed by
measures of endurance (e.g., 6-min walk test [6MWT]), respiratory
function, growth, and quality of life [Hendriksz et al., 2012; Hen-
driksz et al., 2014a; Jones et al., 2015]. In the pivotal phase 3, double-blind, placebo-controlled study including 176 Morquio A patients
with impaired endurance/mobility, elosulfase alfa showed an ac-
ceptable safety profile, comparable with ERTs for other MPS dis-
orders, and a statistically significant impact on walking distance in
the 6MWT after 24 weeks of treatment. No significant impact was
seen in the 3-min stair climb test (3MSCT). In addition, a rapid and
sustained reduction in urine KS (uKS) levels and numerical
improvements in several other efficacy outcomes, including respi-
ratory function and growth, were observed [Hendriksz et al., 2014a;
Hendriksz et al., 2015b].
In this report, we present results from the 27-week primary
treatment phase of an ongoing study evaluating the safety of two
dose levels, 2.0 and 4.0mg/kg/week, of elosulfase alfa in patients
with Morquio A syndrome with a relatively good endurance level/
mobility (required to walk200m at baseline in the 6MWT). The
study evaluated effects on endurance in the 6MWT and 3MSCT
and determined pharmacokinetic parameters and impact on uKS
levels of the two doses. In order to obtain new insights into the
physiology and symptomatology ofMorquio A syndrome, exercise
capacity and various possible physiological contributors to endur-
ance such as cardiac function, respiratory function, and pain in this
study population were assessed as well.MATERIALS AND METHODS
Study Design and Patient Selection
We present results of the primary treatment component of an
ongoing phase 2, two-arm, randomized, double-blind, pilot study
that is being conducted by 8 principal investigators at 8 centers in 4
countries (Germany, United Kingdom, Canada, United States). The
planned study duration is up to 196 weeks, including a 3-week
screening, a 27-week primary treatment phase, and an up to 166-
week extension phase.While safetywas assessed throughout the dura-
tionof the study, efficacy endpointswere assessedover 24 or 25weeks.
Subjects with a documented diagnosis of Morquio A syndrome
who were at least 7 years of age, were able to walk at least 200m in
the 6MWT at screening, and had not previously had a hematopoi-
etic stem cell transplant or been previously treated with elosulfase
alfa were eligible to participate in the study. Patients with severe
untreated sleep apnea (asmeasured by a home sleep testing device),
a requirement for supplemental oxygen or ventilation, or any
medical condition, including but not limited to symptomatic
2274 AMERICAN JOURNAL OF MEDICAL GENETICS PART Acervical spine instability or cord compression, that would interfere
with study participation as determined by the investigator, were
excluded by the protocol. A 6MWTdistance of200m and age7
years were selected as inclusion criteria in order to enroll a
population of subjects who were able to perform a cardio-pulmo-
nary exercise test (CPET) of sufficient duration to provide useful
information on cardio-pulmonary/exercise capacity.
Randomization was stratified by cohort (A or B). The 15 subjects
enrolled in cohortAwere randomized2:1 to receive 2.0 or4.0mg/kg/
week elosulfase alfa and performed all study procedures, including a
CPET. After completion of enrollment in cohort A, 10 additional
subjects were enrolled in cohort B and randomized 1:1 to receive 2.0
or 4.0mg/kg/week elosulfase alfa; cohort B subjects performed all
studyproceduresexcept foraCPET.Thenumberof subjectsrequired
to perform a CPET was limited to 15 due to the complexity of the
procedure. The dose of 4.0mg/kg/week was selected based on the
resultsof thephase1/2clinical studyand invitrostudiesofKuptakeand
lysosomal clearance. Nonclinical safety studies evaluating anaphy-
lactoid-type reactions, formation of anti-elosulfase alfa antibodies
(Abs), adverse events (AEs), and developmental and reproductive
toxicology in rats, rabbits, andmonkeys supported treatment with a
dose up to 4.0mg/kg/week (data on file, BioMarin). The primary
objectiveof theprimary treatmentperiodwas toevaluate the safetyof
2.0 and 4.0mg/kg/week doses of elosulfase alfa. The secondary
objectives were to evaluate the effect of both doses on endurance
(in a 6MWT and 3MSCT), overall exercise capacity, respiratory
function, muscle strength, cardiac function, pain, and uKS levels
and to determine the pharmacokinetic variables of elosulfase alfa.
All patients were pretreated with an appropriate dose of antihis-
tamine medication, with or without antipyretic medications, ap-
proximately 30min before the infusion in order to reduce the risk of
hypersensitivity reactions.The studydrugwas infused intravenously
to deliver the total infusion volumeof either 250 or 400ml (depend-
ing on the subject’s weight) over a period of approximately 4 h.
Treatmentassignmentwasunknowntostudysubjects, investigators,
site personnel, and BioMarin (the sponsor of the study).
The research was prospectively reviewed and approved by the
duly constituted Institutional Review Board, Independent Ethics
Committee, or Research Ethics Board at each participating center.
Safety Evaluation
Safety was assessed throughout the study period by evaluating AEs,
clinical laboratory assessments, vital signs, physical examinations,
electrocardiograms (ECG), echocardiography, immunogenicity,
and pregnancy testing. Severity, seriousness, and relationship to
study drug were determined using the NCI CTCAE v4. Potential
hypersensitivity AEs were identified by utilizing the broad Ana-
phylactic Reaction algorithmic Standardized MedDRA query and
the broad Angioedema Standardized MedDRA query. An infusion
associated reaction (IAR) was defined as any AE, including ana-
phylaxis, anaphylactoid reactions, and other allergic reactions,
occurring after the onset of the infusion and within 1 day following
the end of the infusion, regardless of relationship to study drug.
Serum samples for immunogenicity testing were collected prior
to dose administration at baseline and at weeks 2, 4, 6, 12, and 24.
Routine immunogenicity testing included validated assays for anti-elosulfase alfa total antibody (TAb) and anti-drug Abs that inhibit
binding to the mannose-6-phosphate receptor (neutralizing Abs;
NAb) [Schweighardt B et al., 2014]. Anti-drug IgE, C4 and serum
tryptase were assessedwhen patients experienced a severe IARor an
IAR requiring infusion cessation.
Efficacy Evaluation
Appendix 1 (See Supporting Information Online) provides a
schedule of the secondary efficacy and pharmacokinetic assess-
ments performed during the primary treatment phase.
Endurance was measured in duplicate (7-day time window, one
test/day) at each time point by the 6MWT [American Thoracic
Society, 2002] and the 3MSCT. The outcome of the tests was the
average of duplicate test results. Overall exercise capacity was
measured usingCPET (cohort A only) and performed on a separate
day and after completion of the two endurance tests. Patients
performedmaximal incremental exercise testing using an electron-
ically braked upright cycle ergometer. Expired oxygen and CO2
were analyzed via an expired gas analysis system, heart rate was
monitored by continuous 3- or 12-lead ECG, and oxygen satura-
tion was measured via pulse oximetry. Exercise capacity was
assessed by both the peak workload and peak VO2 (volume of
oxygen uptake) achieved during the CPET. All CPET data were
interpreted centrally in a core laboratory. Respiratory function
(forced vital capacity, forced expiratory volume in 1 s) was assessed
by spirometry in accordance with the American Thoracic Society
Standards [Miller et al., 2005]. A home sleep testing devicewas used
to assess the presence and severity of sleep-disordered breathing by
measurement of blood oxygen saturation, pulse rate, and airflow
during overnight monitoring. Muscle strength (knee extension,
knee flexion, elbow flexion) was measured on a different day from
the 6MWT, 3MSCT, or the CPET using an isokinetic dynamome-
ter. Each test was conducted in triplicate and the maximum of the
triplicate observations was used in the analysis. Cardiac function
was evaluated by a standard 2-dimensional Doppler echocardio-
gram at screening and at week 24 and assessed centrally. Pain was
measured using the Adolescent Pediatric Pain Tool (APPT), a
validated multidimensional tool to evaluate pain in children,
adolescents, and young adults [Jacob et al., 2014]. Within the
APPT, overall pain intensity was evaluated by a Word Graphic
Rating Scale (WGRS), a 10-cmvisual analog scale ranging from“no
pain” (0 cm) to “worst possible pain” (10 cm). Subjects indicated
pain location on a body diagram. uKS was measured by liquid
chromatography tandemmass spectroscopy and normalized using
urinary creatinine [Martell et al., 2011]. Blood samples for phar-
macokinetic analysiswere obtained atweeks 0 and 23within 15min
prior to dosing, 60 and 120min after the start of the infusion, at the
end of the infusion, and 5, 15, 30, 60, 120, and 180min post-
infusion.
Enzyme tests were performed in different laboratories using
different testing protocols and were therefore not comparable. The
enzyme activity levels required for study entry had to be below a
cutoff and were difficult to compare in this range. Basic GALNS
genotyping was not required, but was done in all patients. However,
sophisticated techniques to differentiate heterozygous mutations
were not performed. Given these constraints and the small sample
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genotype or enzyme activity levels to study endpoints.Statistical Methods
The screening assessment values were used as baseline values.
Baseline summaries and safety analysis are descriptive. The safety
analysis included all patientswho received any amount of elosulfase
alfa during the study. Dosing compliance was derived from the
total amount of study drug intake divided by the planned study
drug intake over the study period, and multiplied by 100%.
Efficacy analyses include descriptive statistics for all secondary
efficacy variables. The analyses for all efficacy endpoints were based
on themodified intent-to-treat (MITT) population, consisting of all
subjects who were randomized to study treatment, received at least
one dose of study drug, and had at least one post-treatment obser-
vation. The relationship between immunogenicity and uKS levels
wasassessedby linear regressionanalysis (uKSvs.TAb titersandNAb
positivity rates at week 24) and by plotting the mean percent change
in normalized uKS against visit week, by overall mean TAb titer
group ( or > the overall mean TAb titer) and by NAb positivity
(50% positive, >50% positive) for each treatment group.
Pharmacokinetic parameters of elosulfase alfa were calculated for
the2.0and4.0mg/kg/weekdosegroupsatweeks0and23bystandard
noncompartmental analysis according to current working practices
and using WinNonlin version 6.1 [Shargel et al., 2005]. Actual
sampling times and infusion duration were used in the pharmacoki-
netic calculations as there were some out of the 5% range of the
nominal ones for some subjects. Because of the short elosulfase alfaTABLE I. Patient Demographics and Baseline Characteristics in E
Whole Study G
2.0 mg/kg/week N¼ 15
Age at enrollment (years)
Mean (SD) 14.9 (9.32)
Median (range) 11.3 (7.5, 39.5)
Sex, n (%)
Female 12 (80.0)
Male 3 (20.0)
Race, n (%)
White 14 (93.3)
Other 1 (6.7)
Height percentile, n (%)
<3rd percentile 11 (73.3)
3rd percentile 4 (26.7)
6MWT, m
Mean (SD) 369.6 (89.2)
Median (range) 346.8 (255, 596)
3MSCT, stairs/min
Mean (SD) 65.5 (21.4)
Median (range) 65.3 (28, 119)
uKS, mg/mg
Mean (SD) 16.4 (15.2)
Median (range) 13.0 (1.8, 52.4)
uKS: N¼ 14 in 2.0mg/kg/week and N¼ 9 in 4.0mg/kg/week groups.half-life (mean t1/2 <1 h) relative to dosing interval (1 week), each
infusion was treated as a single dose for pharmacokinetic analysis.
RESULTS
Patient Characteristics
Twenty-five patients were enrolled in the study, including
15 randomized to elosulfase alfa 2.0mg/kg/week and 10 to elosulfase
alfa 4.0mg/kg/week. Baseline characteristics are shown in
Table I. Median age was 11.5 years, with only three patients (in
the 2.0mg/kg/week group) who were older than 18 years. Patients
showed better endurance in the 6MWT and 3MSCT (Table I) than
the subjects assessed in the previous phase 3 study in Morquio A in
which the entry criterion was 6MWT distance 30 and 325m
during screening (mean 6MWT distance 372.2m in this study vs.
203.9–211.9m in the phase 3 study; mean 3MSCT result 65.0 stairs/
min in this study, vs. 27.1–30.0 stairs/min in the phase 3 study)
[Hendriksz et al., 2014a]. Only one patient in this study, in the
2.0mg/kg/week group, used a walking aid during the test. The
majority (80%) of patients showed short stature (height below
3rd percentile), with a mean height of 119.9 cm. The most com-
monly reported medical history findings by preferred term were
arthralgia (40%), body height below normal for age (26.7%), hip
dysplasia (26.7%), pectus carinatum (26.7%), joint laxity (26.7%),
and corneal opacity (26.7%) in the elosulfase alfa 2.0mg/kg/week
groupandarthralgia (60%), kneedeformity (50%), enamelanomaly
(40%), medical device implantation (40%), and medical device
removal (40%) in the elosulfase alfa 4.0mg/kg/week group. All
patients in both treatment groups completed the study.losulfase Alfa 2.0 and 4.0mg/kg/week Dose Groups and in the
roup (Total)
4.0 mg/kg/week N¼ 10 Total N¼ 25
12.0 (3.16) 13.7 (7.5)
12.2 (7.8, 17.6) 11.5 (7.8, 39.5)
4 (40.0) 16 (64.0)
6 (60.0) 9 (36.0)
9 (90.0) 23 (92.0)
1 (10) 2 (8.0)
9 (90.0) 20 (80.0)
1 (10.0) 5 (20.0)
376.3 (70.0) 372.2 (80.6)
393.2 (267, 453) 372.3 (255, 596)
64.2 (23.3) 65.0 (21.7)
63.6 (30, 100) 65.2 (28, 119)
18.8 (9.0) 17.4 (13.0)
17.2 (7.0, 33.3) 13.2 (1.8, 52.4)
TABLE II. Patients Experiencing Adverse Events (AEs) and Infusion Interruptions Due to AEs in the Elosulfase Alfa 2.0 and
4.0mg/kg/week Dose Groups and in the Total Group
2.0 mg/kg/week N¼ 15 4.0 mg/kg/week N¼ 10 Total N¼ 25
Any AE 15 (100.0%) 10 (100.0%) 25 (100%)
Drug-related AE 14 (93.3%) 8 (80.0%) 22 (88.0%)
Any SAE 0 1 (10.0%) 1 (4.0%)
Hypersensitivity AEa 5 (33.3%) 3 (30.0%) 8 (32.0%)
Any IAR 14 (93.3%) 10 (100.0%) 24 (96.0%)
Infusions interrupted due to AEs requiring medical intervention 7/387 (1.81%) 1/264 (0.38%) 8/651 (1.23%)
IAR: infusion-associated reaction; SAE, serious adverse event.
aTwo subjects met anaphylaxis Standardised MedDRA Query but did not meet Sampson’s criteria – events occurred day after infusion
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Dosing compliance was high: 96.1% and 99.2% in the 2.0 and
4.0mg/kg/week groups, respectively. Of the 405 planned infusions
in the 2.0mg/kg/week treatment group, 18 (4.4%) were missed,
and of the 270 planned infusions in the 4.0mg/kg/week treatment
group, six (2.2%) were missed.
Over the 27-week primary treatment phase, administration of
elosulfase alfa was generally safe and well tolerated at both doses.
No new or unexpected safety signals as compared to the other
studies were observed. No patients reported AEs that led to
permanent discontinuation of elosulfase alfa or study procedures.
Therewas one seriousAE (SAE; Table II), i.e., a hospitalization for a
medical device (lower extremity metal plates) removal in a patient
in the 4.0mg/kg/week treatment group. The event was judged
unrelated to the study drug andwas ratedmoderate in severity. The
most common AEs reported by the investigator as study drug-
related were headache (46.7%), pyrexia (40.0%), vomiting
(33.3%), nausea (33.3%), abdominal pain (20.0%), and fatigue
(20.0%) in the 2.0mg/kg/week treatment group and headache,
nausea, abdominal pain, fatigue, cough, and dizziness in the
4.0mg/kg/week treatment group (all reported by 20% of patients).
All drug-related AEs were mild to moderate in severity. TheTABLE III. Change From Baseline to Week 24 in 6-min W
Urine Keratan Sulfate (uKS). Modified Intention-T
4.0 mg/kg/week Dose Groups and i
2.0 mg/kg/week N
6MWT distance change from baseline, m
Median 1.4
IQR 32.1, 14.5
3MSCT change from baseline, stairs/mina
Median 1.3
IQR 5.2, 5.3
uKS change from baseline, mg/mgb
Median 4.8
IQR 11.1, 1.2
IQR: interquartile range.
aOne patient in the 2.0mg/kg/week group did not perform the 3MSCT at week 24.
bOne patient in the 2.0mg/kg/week group and one patient in the 4.0mg/kg/week group had no uKnumber of infusions that were interrupted due to AEs and required
medical intervention was low: 7/387 (1.8%) in the 2.0mg/kg/week
group and 1/24 (0.4%) in the 4.0mg/kg/week group (Table II). No
infusions in either treatment group had to be discontinued. All
patients received and tolerated subsequent infusions.
No clinically meaningful changes in vital signs, clinical chemis-
try, hematology, or urinalysis results were observed. None of the
patients had a shift to a clinically significant abnormal ECG from
baseline to week 24.
All patients tested positive for anti-elosulfase alfa TAb by week
6 and remained positive for the duration of the study. Mean TAb
titers were similar across dose groups at each study visit. All
patients tested positive for NAb at least once during the study and
most (23/25) remained positive afterwards. No patients tested
positive for elosulfase alfa IgE during the study. No association
was found between TAb or NAb positivity and decreases in
normalized uKS. Nor was an association found between drug
exposure and occurrence of treatment-emergent AEs toxicity
grade 2, hypersensitivity AEs, or TAb or NAb titers. As the
overall number of subjects who experienced hypersensitivity AEs
was low (eight patients), it was difficult to reliably identify a
relationship between TAb titers and hypersensitivity AEs.alk Test (6MWT), 3-min Stair Climb Test (3MSCT), and
o-Treat Analysis Set in Elosulfase Alfa 2.0 and
n the Whole Study Group (Total)
¼ 15 4.0 mg/kg/week N¼ 10 Total N¼ 25
1.2 1.4
9.9, 5.1 29.3, 6.9
13.9 4.8
5.3, 25.8 3.6, 11.3
8.4 6.3
14.9, -6.0 14.7, -1.9
S data at both baseline and week 24.
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6MWT, 3MSCT, and uKS. Table III shows changes from
baseline at week 24 in 6MWT, 3MSCT, and uKS for the 2.0 and
4.0mg/kg/week dosing cohorts and for the whole patient group. At
baseline, the mean distance walked in the 6MWT was 372.2m (SD
80.6), and patients climbed a mean of 65.0 stairs (SD 21.7) per min
in the 3MSCT (Table I). No changes from baseline were seen in the
6MWT at either dose at 12 or 24 weeks (Table III). Numerical
improvements from baseline in the 3MSCT were seen in the
4.0mg/kg/week group, but not in the 2.0mg/kg/week group
(Table III). Baseline normalized uKS was 17.4mg/mg normalized
creatinine and decreased substantially in both treatment groups.
Although there was a more rapid and larger mean percentage
decline from baseline observed in the 4.0mg/kg/week dose group
(37.4 and55.5% in the 2.0 and 4.0mg/kg/week groups, respec-
tively, at week 24), mean absolute changes were similar between
groups: 8.0 (SD 9.9)mg/mg and 10.7 (SD 6.1)mg/mg, respec-
tively (Fig. 1; median changes and interquartile ranges are shown in
Table III). Both groups achieved similarmean levels of uKS at week
24, i.e., 8.2mg/mg (SD 6.1) and 7.4mg/mg (SD 4.2) in the 2.0 and
4.0mg/kg/week groups, respectively.
Pharmacokinetics. Pharmacokinetic parameters for both
doses of elosulfase alfa are listed in Appendix 2 (see Supporting
Information online). Half-life (t1/2) was similar in both dosing
groups. The mean t1/2 was approximately 6min at week 0 for both
dosing groups and increased to 23.2 and 31.1min at week 23 for the
2.0 and 4.0mg/kg/week dose groups, respectively. Following repeat
dosing, AUC0-t and Cmax increased by 48 and 44%, respectively, at
week 23 compared to week 0 for the 2.0mg/kg/week dose group,
and by 69 and 100%, respectively, for the 4.0mg/kg/week dose
group.Differences between the 2.0 and 4.0mg/kg/week doses in the
mean AUC0-t and Cmax were greater than dose proportionately,
which indicates that the pharmacokinetics of elosulfase alfa are notFIG. 1. Mean normalized urine keratan sulfate (uKS) versus time. Modifielinear over this dose range. Evaluation of pharmacokinetic versus
pharmacodynamics and efficacy data showed a positive relation
between elosulfase alfa exposure (AUC0-t and Cmax) at week 23 and
uKS % change from week 0 to week 24. A positive correlation was
also found with changes in the 3MSCT, but not with changes in the
6MWT or maximum voluntary ventilation (MVV). The correla-
tion with 6MWT, 3MSCT, and MVV was assessed as these were
important efficacy measures in the phase 3 study. These results
should be interpreted with caution because of the limited number
of patients in these analyses.
Other secondary endpoints. Because of the small sample size
and because differences between the 2.0 and 4.0mg/kg/week
groups in the endurance endpoints were difficult to interpret
due to the heterogeneity of the disease, data from both dosing
groups are presented together for the remainder of the secondary
efficacy endpoints (Table IV and Appendix 3 in Supporting
Information online).
CPET was conducted in 10 patients receiving elosulfase 2.0mg/
kg/week and in five patients receiving 4.0mg/kg/week. At baseline,
weight-adjusted peak oxygen uptake (VO2) wasmildly/moderately
impaired (Appendix 3 in supporting information online), with a
mean baseline value of 30.7ml/kg/min (SD 7.5) (62% of predicted
on average). Therewas no evidence of dynamic cardiac impairment
in these subjects based on relatively stable ejection fraction meas-
urements. CPET data at 25 weeks showed a positive change in
exercise capacity: exercise duration, peak workload, and O2 pulse
increased with treatment (Table IV, Fig. 2, Appendix 3 in Support-
ing Information online). Oxygen uptake relative to work (VO2/
watt) decreased (improved) (Table IV), indicating that patients
were performing work at a reduced oxygen cost.
Overall, pulmonary function tests showed positive changes from
baseline at week 24 for most test variables (Table IV), consistent
with the phase 3 study.d intention-to-treat population. Error bars represent standard errors.
TABLE IV. Median % Change From Baseline to Week 24/25 in
Cardio-Pulmonary Function Test (CPET), Respiratory Function
Tests, and Muscle Strength Tests and Pain Evaluation
(Adolescent Pediatric Pain Tool, APPT) in the Whole Study
Group. Modified Intention-To-Treat Analysis Set
N
Median % change
(IQR)
CPET
Exercise duration, min 15 þ16.9 (1.0, 23.1)
Peak VO2, ml/kg/min 15 þ5.3 (6.3, 31.7)
O2 pulse, ml/beat 15 þ10.7 (1.3, 19.8)
Peak workload, watts 15 þ26.5 (5.1, 42.4)
Aerobic efficiency, ml/watt 14 7.6 (11.9, 0.8)
Respiratory function
Maximum voluntary ventilation,
L/min
21 þ6.2 (7.7, 21.2)
Forced vital capacity, L 24 þ5.4 (0.6, 10.4)
Forced expiratory volume in 1 s, L 24 þ3.4 (4.7, 12.2)
Forced inspiratory vital capacity, L 24 0.4 (5.3, 9.3)
Forced expiratory time, s 21 þ2.0 (4.1, 36.5)
Total lung capacity, L 16 þ0.3 (7.8, 17.1)
Muscle strength
Knee extension, Nm 25 þ11.5 (9.4, 26.5)
Knee flexion, Nm 24 þ2.9 (20.2, 19.3)
Elbow flexion, Nm 19 þ7.1 (28.1, 43.6)
APPT
Pain intensity 19 30.6 (74.4, 4.1)
IQR: interquartile range.
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moderately impaired knee extension (Appendix 3 in Supporting
Information online). The most meaningful numerical improve-
ments in muscle strength versus baseline at week 25 were seen in
knee extension (a median improvement of 11%; Table IV); smaller
improvements occurred in elbow and knee flexion.
The APPT results showed amean baseline pain intensity score of
4.6 on the WGRS (Appendix 3 in Supporting Information online),
corresponding to categorical scores of “medium pain” on the scale.
The lower extremities were identified most frequently as an area
where pain was experienced at baseline (by 68.0% of patients),
followed by the upper extremities (32%) and the head and neck
(32%). The mean pain intensity score on the APPT WGRS de-
creased (improved) numerically from 4.6 at baseline to 3.2 at 24
weeks (Appendix 3 in Supporting Information online), with the
median % change from baseline being 30.6 (Table IV).
Echocardiogram data showed no clear evidence of an effect of
elosulfase alfa on cardiac function after 24 weeks of therapy (data
not shown). Home sleep testing showed no clear trends after 24
weeks (data not shown).DISCUSSION
This study provides additional safety and tolerability data on the
approved dose of elosulfase alfa (2.0mg/kg/week) as well as ahigher dose (4.0mg/kg/week) in patients with Morquio A syn-
drome. In addition, this is the first study to comprehensively
explore aspects of exercise capacity, muscle strength, and pain
in Morquio A patients in order to provide new insights into the
physiology and symptomatology of this disease.
The safety analysis did not reveal any new or unexpected safety
signals, including IARs and hypersensitivity AEs, that were not
observed in previous studies [Hendriksz et al., 2012; Hendriksz
et al., 2014a]. Safety results were similar for the two dosing groups,
with AEs reported by the investigator as study drug-related occur-
ring in similar system organ classes and of similar type. In line with
what has been described previously [Hendriksz et al., 2012; Hen-
driksz et al., 2014a], study drug-related AEs were mild to moderate
in severity. The only SAE that was reported, hospitalization for
medical device removal, was unrelated to the study drug. All
patients developed anti-elosulfase alfa TAbs and NAbs during
the study, which mostly remained positive for the duration of
the study, but no relation between antibody titers and endurance
outcomes, uKS changes, or hypersensitivity reactions could be
established.
In the past, several studies have used endurance tests such as the
6MWT, andmore recently the 3MSCT, to assess the impact of ERT
on overall disease progression in MPS disorders [Harmatz et al.,
2006; Hendriksz et al., 2014a; Muenzer et al., 2006; Wraith et al.,
2004]. However, the physiological correlates of these tests are not
well characterized. As indicated by the American Thoracic Society,
the 6MWT evaluates the global and integrated responses of various
systems working together, including the pulmonary and cardio-
vascular systems, systemic circulation, peripheral circulation,
blood, neuromuscular units, and muscle metabolism [American
Thoracic Society, 2002]. In patients with Morquio A syndrome,
multiple variables may contribute to performance in endurance
tests, including changes in cardiovascular function, pulmonary
function, skeletal muscle function, joint pain, and mechanical
changes resulting from effects on skeletal dysplasia and deformity.
This means that the impact of treatment on the 6MWT will differ
between patients with different clinical manifestations. Despite
limitations inherent to the study design, the present study collected
important pilot data from a wide range of functional tests that may
help to generate hypotheses regarding their interrelation with
patient disabilities and how they are addressed with ERT.
The secondary efficacy measures 6MWT, 3MSCT, and uKS of
the present study were the primary and secondary outcomes of the
pivotal phase 3 study. The previous study showed differences
between the placebo and elosulfase alfa 2.0mg/kg/week groups
after 24weeks of treatment for 6MWTand uKS, but not for 3MSCT
[Hendriksz et al., 2014a]. In the present uncontrolled study, uKS
changed considerably from baseline after treatment in both dose
groups, reaching similar mean and median absolute levels in both
groups. No meaningful changes from baseline in 6MWT distance
were seen in either dose group. The lack of impact in the 6MWT
may be due to the inclusion criteria designed to recruit a study
population healthy enough to complete the CPET, muscle strength
tests, and other efficacy measures. Mean baseline walking distance
was 372m, considerablymore than the values of around 200m seen
in the phase 3 study [Hendriksz et al., 2014a]. The fact that walking
distances were closer to normal in this patient group (i.e., 70–80%
FIG. 2. Box plots showing median, interquartile ranges, and ranges of cardio-pulmonary exercise testing outcomes at baseline and week 25
(N¼ 15). Modified intention-to-treat population.
BURTON ET AL. 2279of that of an unaffected population [Lammers et al., 2008; Li et al.,
2007]) may have made it more challenging to show improvement
and could possibly account for the lack of change in 6MWT
distance in this study. Also, these patients can probably not be
expected to reach 6MWT distances comparable to healthy (unaf-
fected) age/height-matched controls due to the presence of skeletal
and joint abnormalities. The 6MWT is a multi-systemic test,
though improvement may not be demonstrated in this endpoint
in each individual benefiting from treatment due to the heteroge-
neity of the disease and variable impact of ERT on outcomes.
Results of the 3MSCT also showed that patients in this study had a
relatively high level of function, with the number of stairs climbed
per minute at baseline being more than twice that seen in the phase
3 and MorCAP studies [Harmatz et al., 2013; Hendriksz et al.,
2014a]. After 24 weeks of treatment, the 3MSCT showed a numer-
ical improvement at the higher dose, but not at the lower dose,
though there was a high degree of variability at both baseline and
outcomes among subjects for this test. However, the present
descriptive study was not powered to show statistically significant
differences between groups given the large number of endpoints,
the small sample size, and the clinical heterogeneity of the study
population. Also, no conclusions can bemade regarding the impact
of elosulfase alfa on endurance based on these data as there was nocontrol group. Larger controlled studies would be needed to
further investigate the observed differences between dose groups.
The uKS data from both dosing groups suggested no obvious
correlation with efficacy. Although a more rapid and larger per-
centage decline in uKS from baseline was observed with the 4.0mg/
kg/week dose than with the lower dose, the relevance of this finding
is difficult to assess: Absolute changes in uKS were similar in both
treatment groups, and both groups achieved a similar uKS level
after 24weeks.Moreover, as previously indicated, the studywas not
powered to detect significant differences between doses. uKS has
been suggested to be a biomarker of clinical severity in Morquio A
syndrome [Harmatz et al., 2013], but no clear link between
treatment-induced uKS changes and clinical efficacy could be
established in clinical studies thus far.
The most noteworthy findings of this study are that patients
overall showed impaired exercise capacity andmuscle strength and
considerable pain, predominantly in the lower extremities, at
baseline, several components of which showed numerical improve-
ment after 24–25 weeks of treatment in both dose groups. The
improvements seen in the 4.0mg/kg/week dose group were larger
than those seen in the 2.0mg/kg/week dose group, particularly for
the CPET and muscle strength variables. However, as the small
sample size does not allow for any conclusions to be drawn on dose,
2280 AMERICAN JOURNAL OF MEDICAL GENETICS PART Adata were not shown for the different doses separately. It is
interesting that the improvements seen in peak attainableworkload
and other CPET variables (exercise duration, O2 pulse, and aerobic
efficiency) were not associated with 6MWT distances, which
remained essentially unchanged over the same period of time in
the same study population. The contrasting results may have
resulted partly from the difference in the effort-dependence of
the two tests.Whereas the 6MWT is fundamentally a volitional test,
largely depending on self-motivational factors that vary widely
among patients, CPET is specifically designed to measure maximal
exercise capacity while controlling for motivational factors. In the
6MWT, orthopedic abnormalities, such as genu valgum and ankle
laxity/varus, could also explain why no increase was seen, even
though exercise capacity was improved. At the same time, the
observed improvements in aerobic efficiency suggest a mechanism
for symptom improvement independent of exercise capacity, i.e.,
subjects experiencing less fatigue for the same amount of work
performed. In the phase 3 study, patients treated with elosulfase
alfa reported less fatigue than patients on placebo (data on file,
BioMarin). The results of the present study provide a possible
mechanism of action for explaining this observation. The CPET
outcomes must be interpreted with caution as there could be a
training effect that cannot be addressed due to the lack of a
placebo group.
The APPT showed a pain burden at baseline, predominantly in
the lower extremities, which confirms the findings from a patient-
reported outcomes study inMorquioApatients inwhich 64%of 36
children and 74%of 27 adults reported joint pain,most often in the
lower extremities [Hendriksz et al., 2014b]. Pain was also consid-
erably reduced from baseline by ERT in this pilot study. A recent
study reported a minimal clinically important difference of
12.5% in pain intensity, as determined by a 0–10 point numerical
rating scale, in 153 adolescents with chronic pain [Hirschfeld et al.,
2014], which is less than the reduction seen in our study (median
change of 30.6%). Therefore, acknowledging the limitations of
this small study, these findings suggest that the effect seen on pain
intensity may be clinically important. The impact of treatment on
respiratory function tests was limited. However, the patients in this
study showed relatively good respiratory function (MVV and
forced vital capacity) at baseline compared with the phase 3 study,
which means that there may have been less room for improvement
[Hendriksz et al., 2014a].
Overall, we can conclude that in this population of patients with
a relatively good endurance/functional capacity, elosulfase alfa at
4.0mg/kg/week had an acceptable safety and tolerability profile,
similar to the profile previously observed at lower doses in more
impaired populations. There was little change in endurance and
respiratory endpoints, which might be due to the relatively healthy
population (causing a ceiling effect), clinical heterogeneity, and
small sample size. However, positive changes were observed in
exercise capacity, muscle strength, and pain in subjects from both
dose groups. These endpoints warrant further exploration as they
may provide new insights into the physiology and symptomatology
of Morquio A syndrome. The results of this study should be
interpreted in light of the exploratory nature of the study, the
small sample size, and the lack of a control group.ACKNOWLEDGMENTS
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